cryopyrin-associated periodic syndromes
Rare disease · 2014–2017
4decisions
2medicines
1carried consumer input
9individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| anakinra Amendment of PBS listing from Authority Required (STREAMLINED) to Authority Required for treatment of patients with moderate to severe cryopyrin associated… | Jul 2017 | Not recommended | none received |
| canakinumab Treatment of adults and children with moderate to severe cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome,… | Nov 2017 | Recommended with restriction | none received |
| anakinra Treatment of cryopyrin-associated periodic syndromes (CAPS). | Jul 2015 | Recommended with restriction | no section in document |
| anakinra Treatment of cryopyrin-associated periodic syndromes (CAPS) in adult and paediatric patients aged 8 months and older with a body weight of 10 kg or above. | Nov 2014 | Recommended with restriction | 9 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.